Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy.
corticosteroids
immune-related adverse events
immunotherapy
melanoma
priming-phase
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Jun 2023
03 Jun 2023
Historique:
received:
26
03
2023
revised:
29
05
2023
accepted:
01
06
2023
medline:
10
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
Successful treatment with Immune Checkpoint Inhibitors (ICI) requires the balanced activation of the immune system. Over-activation may result in immune-related adverse events (irAEs), which often require steroidal treatment. This study examined the possible impact of steroids on treatment efficacy in melanoma patients concerning initiation timing and dosage. A retrospective, single-center analysis of patients with advanced melanoma who underwent first-line ICI therapy during 2014-2020 was conducted. Among the 415 patients, two-hundred patients (48.3%) were exposed to steroids during the first line, most of them due to irAEs ( Early exposure to corticosteroids during the priming phase of ICI therapy could impede the establishment of an effective immune response. These results suggest that caution should be exercised when considering the use of steroids for the management of early-onset irAEs.
Sections du résumé
BACKGROUND
BACKGROUND
Successful treatment with Immune Checkpoint Inhibitors (ICI) requires the balanced activation of the immune system. Over-activation may result in immune-related adverse events (irAEs), which often require steroidal treatment. This study examined the possible impact of steroids on treatment efficacy in melanoma patients concerning initiation timing and dosage.
METHODS
METHODS
A retrospective, single-center analysis of patients with advanced melanoma who underwent first-line ICI therapy during 2014-2020 was conducted.
RESULTS
RESULTS
Among the 415 patients, two-hundred patients (48.3%) were exposed to steroids during the first line, most of them due to irAEs (
CONCLUSIONS
CONCLUSIONS
Early exposure to corticosteroids during the priming phase of ICI therapy could impede the establishment of an effective immune response. These results suggest that caution should be exercised when considering the use of steroids for the management of early-onset irAEs.
Identifiants
pubmed: 37297003
pii: cancers15113041
doi: 10.3390/cancers15113041
pmc: PMC10252883
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA Dermatol. 2016 Jan;152(1):45-51
pubmed: 26501224
JAMA. 2021 Feb 16;325(7):686-687
pubmed: 33591334
J Exp Med. 2019 Dec 2;216(12):2701-2713
pubmed: 31537643
Eur J Cancer. 2020 Jun;132:61-70
pubmed: 32334337
J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289
pubmed: 30865922
J Immunother Cancer. 2018 Jun 11;6(1):51
pubmed: 29891009
Front Oncol. 2021 Mar 05;11:607531
pubmed: 33747922
JAMA Oncol. 2020 Apr 1;6(4):519-527
pubmed: 31895407
Nat Rev Dis Primers. 2020 May 7;6(1):38
pubmed: 32382051
Oncologist. 2018 Nov;23(11):1358-1365
pubmed: 29934411
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Molecules. 2021 Sep 24;26(19):
pubmed: 34641331
JAMA Oncol. 2019 Jun 1;5(6):906-908
pubmed: 30998826
J Thorac Oncol. 2017 Dec;12(12):1798-1805
pubmed: 28939128
J Clin Oncol. 2015 Oct 1;33(28):3193-8
pubmed: 26282644
Eur Heart J. 2023 May 13;:
pubmed: 37178179
JAMA Oncol. 2018 Mar 01;4(3):374-378
pubmed: 28975219
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32152222
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
Lung Cancer. 2018 Jan;115:71-74
pubmed: 29290265
Cancers (Basel). 2021 Jun 20;13(12):
pubmed: 34203061
BMC Cancer. 2019 Oct 21;19(1):974
pubmed: 31638948
J Immunother Cancer. 2019 Nov 15;7(1):306
pubmed: 31730012
Lancet Oncol. 2016 Nov;17(11):1558-1568
pubmed: 27622997
Eur J Cancer. 2016 Nov;67:46-54
pubmed: 27596353
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
Urol Oncol. 2019 Jun;37(6):355.e21-355.e29
pubmed: 30935847
Eur J Cancer. 2017 Sep;82:80-91
pubmed: 28651159
J Clin Oncol. 2017 Dec 1;35(34):3807-3814
pubmed: 28841387
Cancers (Basel). 2020 Feb 27;12(3):
pubmed: 32120803
Nat Rev Rheumatol. 2021 Apr;17(4):213-223
pubmed: 33686279
Clin Cancer Res. 2021 Nov 1;27(21):5993-6000
pubmed: 34376536
Front Oncol. 2021 Mar 01;11:631949
pubmed: 33732650
J Oncol. 2019 Apr 28;2019:5269062
pubmed: 31182961
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Endocr Rev. 2019 Feb 1;40(1):17-65
pubmed: 30184160
Oral Oncol. 2020 Dec;111:105013
pubmed: 32977184
Eur J Cancer. 2017 Nov;86:115-124
pubmed: 28987768
BMC Med. 2020 Apr 20;18(1):87
pubmed: 32306958
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
J Clin Oncol. 2019 Oct 20;37(30):2730-2737
pubmed: 31116675
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33154150
Lancet Oncol. 2020 Aug;21(8):e398-e404
pubmed: 32758477
J Thorac Oncol. 2018 Nov;13(11):1771-1775
pubmed: 29935305
Front Oncol. 2021 Apr 12;11:633032
pubmed: 33912454
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34226279
J Clin Oncol. 2015 Mar 1;33(7):773-81
pubmed: 25605840
Cell Rep. 2014 May 22;7(4):938-9
pubmed: 24856295
ESMO Open. 2019 Feb 27;4(1):e000457
pubmed: 30964126
Melanoma Res. 2021 Jun 1;31(3):208-217
pubmed: 33904517
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
Nat Rev Clin Oncol. 2022 Apr;19(4):269-280
pubmed: 35039679
Cancer Manag Res. 2020 Jun 16;12:4585-4593
pubmed: 32606951